Use of botulinum toxin type A in patients with erythematous-telangiectatic rosacea
The article describes relevant data on the etiology of rosacea and the clinical forms of the disease. A pathogenetic substantiation of the feasibility of using botulinum toxin type A (BTA) with an erythematous-telangiectatic subtype of rosacea is given. A study was conducted involving 30 patients with ETR to treat the manifestations of this dermatosis using BTA injections in mesotechnics. As a result, we established a positive role for the use of BTA in ETP based on the use of a visual analogue scale (VAS), and also obtained data on the distribution of trigger factors and associated pathologies. We came to conclusions about the effectiveness of the botulinum toxin method for rosacea and the feasibility of further studies to optimize the dose and frequency of administration of type A botulinum toxin for a more pronounced and lasting result.